Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Soft Matter

Sec. Liquid Crystals

Volume 5 - 2025 | doi: 10.3389/frsfm.2025.1658466

Recent Advances in Lyotropic Liquid Crystal Nanoparticle Formulations for Drug Delivery Systems

Provisionally accepted
  • Sri Shanmugha College of Pharmacy, Sangagiri, India

The final, formatted version of the article will be published soon.

Lyotropic liquid crystalline (LLC) nanoparticles have gained significant attention as drug delivery systems owing to their unique self-assembly properties, biocompatibility, and ability to encapsulate both hydrophilic and hydrophobic drugs. This chapter explores recent advances in LLC formulations, focusing on their structural classification, physicochemical properties, and applications in controlled-drug delivery. Various mesophases, including lamellar, cubic, and hexagonal structures, have been discussed, highlighting their roles in controlled release. A comparative analysis reveals that cubic phases offer superior structural stability for sustained release, while hexagonal phases excel in high-viscosity applications, though their complex preparation limits scalability. In addition, key characterization techniques such as small-angle X-ray scattering, differential scanning calorimetry, and rheology are examined to offer insights into their stability and performance. Furthermore, the development of in situ gelling precursor systems and their applications in oral, transdermal, ocular, nasal, injectable, and periodontal drug delivery have been explored. The incorporation of stimuli-responsive materials into LLC systems enhances their adaptability to personalized medicine and advanced therapeutic strategies. Despite these advancements, challenges such as scalability, long-term stability, and clinical translation remain unresolved. This chapter highlights the potential of LLC nanoparticles to revolutionize modern drug delivery by improving bioavailability, therapeutic efficacy and patient compliance. Future research should focus on optimizing formulation strategies and exploring novel biomaterials to expand the clinical utility of LLC-based drug delivery systems.

Keywords: bioavailability, drug delivery system, lyotropic liquid crystals, liquid crystalline phase, nanoparticle

Received: 02 Jul 2025; Accepted: 25 Aug 2025.

Copyright: © 2025 Subash and Khute. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Sulekha Khute, Sri Shanmugha College of Pharmacy, Sangagiri, India

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.